08:57 uur 21-07-2015

ERYTECH: positieve veiligheidsbeoordeling ERY-ASP in tweedefaseonderzoek naar alvleesklierkanker

LYON, Frankrijk–(BUSINESS WIRE)– ERYTECH Pharma, het Franse biofarmaceutische bedrijf dat innovatieve behandelingen tegen acute leukemie en andere kankersoorten door middel van ‘uithongering’ van tumoren ontwikkelt, heeft een positieve beoordeling van het veiligheidscontrolecomité  (DSMB) gekregen nadat 24 alvleesklierkankerpatiënten zijn behandeld met ERY-ASP in het kader van zijn fase 2-onderzoek.

De ERY-ASP-studie is een in meerdere centra uitgevoerd en gerandomiseerd onderzoek naar de tweedelijnszorg voor patiënten met uitgezaaide alvleesklierkanker. Onderzoekers vergelijken in dit onderzoek, waaraan circa negentig patiënten meewerken, ERY-ASP in combinatie met standaardzorg (Gemcitabine- of FOLFOX-kuur) met standaardzorg alleen in een randomisatie van 2 op 1. Het primaire eindpunt is progressievrije overleving van vier maanden.

ERYTECH announces positive safety review for ERY-ASP in its Phase 2 study in pancreatic cancer

LYON, France–(BUSINESS WIRE)– Regulatory News: ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris – ERYP; OTC US – EYRYY), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, announces a positive DSMB safety review following the treatment of the first twenty-four patients with ERY-ASP in its Phase 2 study in pancreatic cancer.

The ERY-ASP pancreatic cancer Phase 2 study is a multicenter, randomized trial in second-line treatment of patients with metastatic pancreatic cancer. In this study of approximately 90 patients, conducted in France, ERY-ASP in addition to the standard of care (Gemcitabine or FOLFOX regimen) is being compared to the standard of care alone in a 2-to-1 randomization. The primary endpoint is progression-free survival (PFS) at 4 months.

A pre-planned safety analysis of the first 24 patients treated has now been performed by an independent Data Safety Monitoring Board (DSMB). The DSMB raised no safety concerns, and recommended the continuation of enrollment in the study.

Two earlier DSMB reviews recommended proceeding with the combination of ERY-ASP with Gemcitabine and FOLFOX after safety evaluation of the first three patients in each treatment regimen.

A DSMB is an independent external committee of clinical research experts who review data in ongoing clinical trials with particular attention to safety.

“Our earlier Phase 1 study in pancreas cancer with ERY-ASP in monotherapy had already suggested a favorable safety profile of the product candidate. We are pleased that this DSMB raised no safety concerns for the combination of ERY-ASP with the current standard of care. If this safety profile can be confirmed and signals of efficacy can be observed, we believe that the results of this Phase II clinical trial could pave the way for treatment of other solid tumors”, comments Iman El-Hariry, Chief Medical Officer of ERYTECH Inc.

About ERYTECH and ERY-ASP/GRASPA®: www.erytech.com

Created in Lyon in 2004, ERYTECH is a French biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside red blood cells, ERYTECH has developed a pipeline of product candidates targeting markets with high unmet medical needs. ERYTECH’s initial focus is on the treatment of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). The company has recently announced positive Phase 3 trial results with its lead product candidate, ERY-ASP/GRASPA®, in children and adults with relapsed or refractory ALL. ERY-ASP/GRASPA consists of an enzyme, L-asparaginase, encapsulated inside donor-derived red blood cells. L-asparaginase depletes asparagine, a naturally occurring amino acid essential for the survival and proliferation cancer cells, from circulating blood plasma. ERYTECH has also commenced clinical trials of ERY-ASP in the United States as a potential first-line therapy for the treatment of adults with ALL and a Phase 2 clinical trial in Europe evaluating GRASPA as a first-line therapy for the treatment of elderly patients with AML.

Every year over 50,000 patients are diagnosed with ALL or AML, the two forms of acute leukemia in Europe and the United States alone. Today, for about 80% of these patients, mainly adults and relapsing patients, current forms of L-asparaginase cannot be used due to their toxicity. With its improved safety profile, ERYTECH is developing ERY-ASP/GRASPA® to allow all leukemia patients to be treated, even the most fragile ones.

ERYTECH believes that ERY-ASP could also be used to treat solid tumors and is conducting a Phase 2 clinical trial in Europe in patients with pancreatic cancer. In addition to its current product candidates that focus on using encapsulated enzymes to induce tumor starvation with reduced side effects, ERYTECH is exploring the use of its platform for developing cancer vaccines and enzyme replacement therapies.

ERYTECH has obtained orphan drug designations for ERY-ASP/GRASPA® in ALL, AML and pancreas cancer, both in Europe and the USA. ERYTECH produces ERY-ASP/GRASPA® at its own GMP-approved and operational manufacturing site in Lyon (France), and at a site for clinical production in Philadelphia (USA). The company has entered into licensing and distribution partnership agreements for ALL and AML in Europe with Orphan Europe (Recordati Group), and for ALL with TEVA in Israel.

ERYTECH is listed on Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP) and is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes. ERYTECH is also listed in the US under an ADR level 1 program (OTC, ticker EYRYY).

Forward-looking information

This document may contain forward-looking statements and estimates with respect to the financial situation, the results of operations, the strategy, the project and to the anticipated future performance of ERYTECH and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond the Company’s control. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. Therefore, actual results, the financial condition, performance or achievements of ERYTECH, or industry results, may turn out to be materially different from any future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Documents filed by ERYTECH Pharma with the French Autorité des Marchés Financiers (www.amf-france.org), also available on our website (www.erytech.com) describe such risks and uncertainties. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of the publication of this document. ERYTECH disclaims any obligation to update any such forward-looking statement. Readers are cautioned not to place undue reliance on any of these forward-looking statements. ERYTECH disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in the Company’s expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by French law.


Gil Beyen
Chairman and CEO
Tel: +33 4 78 74 44 38
Julien Perez / Emmanuel Huynh
Investor relations

Press relations
Tel: +33 1 44 71 98 52

Check out our twitter: @NewsNovumpr